Related Experiment Video

Updated: Jul 27, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

448

PD-1/PD-L1 immune checkpoint blockade in ovarian cancer: Dilemmas and opportunities

Zikun Peng1, Ming Li1, Huayi Li1

  • 1Department of Gynaecological Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; National Clinical Research Centre for Obstetrics and Gynaecology, Cancer Biology Research Centre (Key Laboratory of the Ministry of Education), Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Drug Discovery Today
|June 11, 2023
PubMed

Insights

Immune checkpoint inhibitors (ICIs) show limited success in ovarian cancer. This review examines clinical trials, resistance mechanisms, and strategies to improve ICI efficacy by modifying the tumor microenvironment.

Area of Science:

  • Oncology
  • Immunotherapy
  • Cancer Research

Background:

  • Immune checkpoint inhibitors (ICIs) have transformed cancer treatment.
  • Ovarian cancer has shown modest efficacy to ICIs as monotherapy or combination therapy.
  • PD-1/PD-L1 blockade is under investigation for ovarian cancer.

Purpose of the Study:

  • To review completed and ongoing clinical trials of PD-1/PD-L1 blockade in ovarian cancer.
  • To categorize mechanisms of resistance to ICIs in ovarian cancer.
  • To introduce strategies for enhancing ICI efficacy by targeting the tumor microenvironment.

Main Methods:

  • Literature review of clinical trials involving PD-1/PD-L1 inhibitors in ovarian cancer.
  • Analysis of mechanisms contributing to ICI resistance.
  • Exploration of novel therapeutic approaches to modulate the tumor microenvironment.

Main Results:

  • ICIs have demonstrated limited efficacy in ovarian cancer compared to other malignancies.
  • Several mechanisms of resistance to PD-1/PD-L1 blockade have been identified.
  • Strategies to overcome resistance and potentiate ICI activity are being developed.

Conclusions:

  • Ovarian cancer remains a challenge for current ICI therapies.
  • Understanding resistance mechanisms is crucial for developing effective treatments.
  • Modulating the tumor microenvironment holds promise for improving responses to PD-1/PD-L1 antibodies.
Keywords:
PD-1/PD-L1 blockadedrug resistanceimmune checkpoint inhibitorsovarian cancer

More Related Videos

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood06:07

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

5.8K
Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients07:42

Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients

Published on: February 7, 2021

5.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
575